Executives highlight approaches around recent landmark approvals for digital medicine and gene therapy.

In today’s drug development environment, there is no doubt that supply chain decisions are paramount in a product launch strategy, writes Lisa Henderson.

Tackling the limitations of R&D—at different stages of the journey.

Insights on the challenges, activity, and motives in merging the two areas.

Lisa Henderson examines the rise and reach of biopharma in the key Northeast Corridor clusters of Boston, Philadelphia, and New Jersey.

With increasing responsibilities and decision-making post-discovery, the traditional label of “biotech” is changing, writes Lisa Henderson.

A common thread in our exploration of "Emerging Biopharma" is that these companies need to be those that look beyond pure discovery—and put equal effort into the pivot to potential commercialization.

Pharm Exec convenes an expert panel to discuss new ways to navigate the many complexities of assessing business and risk in the life sciences.

PharmExec talks to Dr. Gil Van Bokkelen, co-founder of Athersys, a company looking to forge new advances in the stem cell arena.

With blockchain still in the potential but not proven area of the pharma enterprise, when is the technology the right choice for you?

Although Biogen's Alzheimer's drug candidate BAN2401 addresses buildup of amyloid plaques, investors and scientists look to reevaluate the plaque theory and search for a glimmer of hope in breakthrough treatments.

Lisa Henderson reports on the takeaways from last month's annual gathering of the Pharm Exec Editorial Advisory Board.

Findings from a new ACT and SCORR Marketing survey reveal the most actively used flexible design approaches in clinical research—many with application in rare disease.